Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADC TherapeuticsADCT -2.73%35 3-Year EBITDA Growth Rate is 20.50% as of Mar. 2026, which is 67% above its 10-year median of 12.25. GuruFocus rates ADCT with a GF Score™ of 35/100 and a GF Value™ of $2.08 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 811 Drug Manufacturers companies, ADC Therapeutics ranks better than 68.93% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 20.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 27.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of ADC Therapeutics was 29.40% per year. The lowest was -33.00% per year. And the median was 12.25% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
ADC Therapeutics 3-Year EBITDA Growth Rate Related Terms
ADCT vs LFCR, DERM, BGM: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ADC Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADC Therapeutics 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ADC Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where ADC Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 20.50% mean?
ADC Therapeutics (ADCT) has a 3-Year EBITDA Growth Rate of 20.50% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ADC Therapeutics and its competitors. This is 67% above median its historical median of 12.25. According to the industry distribution chart, ADC Therapeutics ranks #252 out of 811 companies in the Drug Manufacturers industry, placing it in the top 31.1%.
Is ADC Therapeutics' 3-Year EBITDA Growth Rate too high?
ADC Therapeutics' current 3-Year EBITDA Growth Rate of 20.50% is 67% above median its 10-year median of 12.25. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. ADC Therapeutics' value of 20.50% is 133% above this industry median. Based on the distribution chart, ADC Therapeutics ranks #252 out of 811 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ADC Therapeutics has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ADC Therapeutics' 3-Year EBITDA Growth Rate compare to LFCR and DERM?
According to the Drug Manufacturers industry distribution chart, ADC Therapeutics ranks #252 out of 811 companies for 3-Year EBITDA Growth Rate. This puts ADC Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. ADC Therapeutics' value of 20.50% is 133% above this benchmark. While the company's 10-year median is 12.25 vs. the industry median of 8.80, ADC Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADC Therapeutics's current 3-Year EBITDA Growth Rate of 20.50% is 133% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ADC Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADC Therapeutics's current 3-Year EBITDA Growth Rate is 20.50%, which is 67% above median its own 10-year median of 12.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADC Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, ADC Therapeutics (ADCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.08, compared to a current price of $1.07 — trading 48.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 20.50%, which is 67% above median its 10-year median of 12.25 and 133% above the Drug Manufacturers industry median of 8.80. ADC Therapeutics' overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For ADC Therapeutics (ADCT), the current 3-Year EBITDA Growth Rate is 20.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADC Therapeutics (ADCT) Overvalued in 2026?
Based on GuruFocus' analysis, ADC Therapeutics stock appears to be undervalued.
The current stock price of $1.07 is trading 48.6% below its estimated GF Value™ of $2.08.
GuruFocus considers ADC Therapeutics to be Possible Value Trap.
Key valuation signals for ADCT:
3-Year EBITDA Growth Rate: 20.50% (67% above median its 10-year median of 12.25)
GF Value™: $2.08 vs. price of $1.07 (48.6% below fair value)
Industry Position: 133% above the Drug Manufacturers median (#252 of 811)
No single metric tells the full story. See the ADCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
35GF Score
Get the complete analysis for ADCT
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADCT has been successfully added to your 
